Alimera resubmits Iluvien NDA to US FDA in DMO
This article was originally published in Scrip
Executive Summary
Alimera Sciences has resubmitted its new drug application (NDA) to the US FDA for Iluvien (fluocinolone acetonide intravitreal insert), which the company licensed from partner pSivida, as a treatment for diabetic macular oedema (DMO).